Investor Relations

NYSE: NVRO

Price

73.16 +0.00 ( +0% ) 5:00 5/23/17 Pricing delayed 20 minutes

Volume 590,500

Recent News

See All
May 8, 2017 Nevro Reports First Quarter 2017 Financial Results
  Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three months ended March 31, 2017 . First Quarter Highlights: Achieved revenue of $68.4 million in the first quarter of 2017, an increase of 64% as reported, over the same period of the prior year U.S. revenue of $53.1 million in the first quarter of 2017, an increase of 80% over the prior year International revenue of $15.3 million in the first quarter of 2017, an increase of 30% in constant currency and 26% on an as-reported basis, both over the same period of the prior year Initiated controlled commercial launch of Surpass™ surgical leads for the Senza® Spinal Cord Stimulation (SCS) System Presented on clinical and scientific progress at the 2017 North American Neuromodulation Society (NANS) meeting First Quarter Financial Results Revenue for the three months ended March 31, 2017 was $68.4...
May 2, 2017 Nevro to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that its management will be presenting at the Bank of America Merrill Lynch 2017 Health Care Conference on Tuesday, May 16, 2017 in Las Vegas. Nevro management is scheduled to present at 10:40 a.m. PT.  The presentation will be accessible via a live audio webcast, accessible in the "Investors" section of the company's website at: http://www.nevro.com/investors. Following the presentation, an archived copy will be available on the Investor Events and Presentations webpage of the Company's website. About Nevro Headquartered in Redwood City, California , Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza System is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro.

Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro Corp.